D oxorubicin (Adriamycin), an anthracycline glyco side antibiotic, is a potent
chemotherapeutic agent useful in the treatment of a wide variety of tumors (1— 3) …

Methods We studied 36 cancer patients who underwent chemotherapy, including
doxorubicin, to assess [123I] MIBG and 111In-antimyosin uptake in the course of …

To assess myocardial cell damage due to doxorubicin cardiotoxicity, we prospectively
studied 30 patients with sarcomas who were receiving chemotherapy, including doxorubicin …

tors or for patients who are potential candidates for future
repeateddoxorubicinadministration. Althoughtheprogno sis for patients with advanced or …

To assess chemotherapeutically induced myocardial damage, myosin-specific antibody
scans and ejection fraction measurements were performed in 32 patients with breast cancer …

The untimely death of patients from metastatic breast carcinoma and other malignant
neoplasms haunts all medical professionals. The tumoricidal potency of doxorubicin …

A patient with primary hepatoma, treated with doxorubicin and presenting with atypical
electrocardiographic findings, was investigated with myosin-specific monoclonal antibody …

Background In patients with cardiac dysfunction due to anthracycline-induced myocyte
damage, continuation of anthracyclines carries a high risk, and modification of …

Abstract 11 In antimyosin scintigraphy was evaluated at various cumulative anthracycline
dose levels in order to early identify patients with severe cardiac injury and increased long …

The objective of this review is to make physicians aware of new radionuclide methods to
detect cardiac effects of chemotherapeutic drugs. This knowledge is important because of …